Eli Lilly Eyes Oura IPO Stake as GLP-1 and Wearables Converge
Eli Lilly has signaled it may buy up to $100 million of Oura stock in the wearable company’s IPO, alongside a possible $300 million cornerstone investment from Dragoneer. The combined commitments would represent about $400 million, or nearly 19% of the offering. The move reflects Lilly’s interest in pairing GLP-1 therapies such as tirzepatide with continuous biometric monitoring to support chronic disease management.
Eli Lilly has indicated it could purchase as much as $100 million of Oura common stock in the wearable company’s IPO. Dragoneer Investment Group may commit up to $300 million as a cornerstone investor. Together, those potential commitments equal roughly $400 million, or almost one-fifth of the base offering.
Oura plans to list on Nasdaq under OURA, offering 50 million shares at $40–$44. Existing stockholders are selling 36.5 million shares, while Oura issues 13.5 million; much of the primary proceeds is designated for tax withholding tied to equity award settlement. Lilly’s tirzepatide brands are Mounjaro and Zepbound.
If Lilly links GLP-1 treatments with Oura’s sensors, patients managing diabetes or obesity may gain more continuous feedback on sleep, activity, and recovery, potentially improving adherence and titration. Clinicians could receive richer remote data, though privacy, data ownership, and unequal device access may shape benefits. Wearable makers and drugmakers may deepen partnerships, making health monitoring more integrated but also more commercialized.